Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report. (July 2021)

• Record Type: Journal Article
• Authors: Guven, Deniz Can; Kilickap, Saadettin; Yildirim, Hasan Cagri; Ceylan, Furkan; Bas, Onur; Dizdar, Omer
• Is Part Of: Journal of oncology pharmacy practice. Volume 27:Number 5(2021)
• Page Start: 1281
• Page End: 1283
• Publication Date: 2021-07
• Subjects: Ewing sarcoma -- nivolumab -- immunotherapy; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155220965677
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: Although, immune check-point inhibitors changed the course of many cancers, the outcomes in sarcomas were rather disappointing with less than 10% response rates. Ewing sarcoma is a poorly differentiated and aggressive tumor mostly seen in the children and adolescents. It's a distinct type of sarcoma with prominent chemosensitivity in the early stages. However, the relapsing disease has a poor prognosis with limited treatment options. Case report: Herein, we represent a case of relapsed Ewing sarcoma treated with multiple lines of chemotherapy. Management & outcome: The patient had a very good response to salvage treatment with a combination of paclitaxel and nivolumab which lasted for twelve months after the cessation of treatment. Discussion: We think that chemotherapy plus immunotherapy can be an option for Ewing sarcoma patients treated with multiple lines of chemotherapy.